Case Analysis 3 – Ending HIV? Sangamo Biosciences and the Gene Editing
Please answer the following questions: What were the pros and cons of Sangamo pursuing its gene editing programs alone versus working with a partner? Does the HIV program offer any special opportunities or challenges? What do you think Sangamo should do regarding the HIV program? Should it license the technology to a larger pharmaceutical? Should it form a joint venture with another biotech or pharma company? If so, who? Importantly, apply as many of the COs (Course Objectives) as you can to the case. These are given for reference below.
Your Case should be at least 3 pages, have at least four (4) references using APA format (you may use one or two references cited from the case but you should have at least two additional unique reference from your own research)